Key result
In prostate cancer sera with high hK2 levels, hK2 exists as a 90-kDa complex with alpha1-antichymotrypsin and a predominant 32-kDa free form including the precursor prohK2.
Observational
Human glandular kallikrein (hK2) exists in both complexed and free forms in prostate cancer serum, with the free form predominating.
Answers are grounded in this paper and cite their sources.
hK2 forms in prostate cancer sera warrant assay refinement; leaves open prognostic value pending human validation.
Forms of human glandular kallikrein (kK2) in prostate carcinoma serum were identified using monoclonal antibodies specific for hK2 and prohK2. Recombinant mammalian hK2, prohK2, and prostate = specific antigen (PSA) were utilized to confirm the specificity of monoclonal antibodies for hK2 and the lack of reactivity with PSA. In prostate cancer patient sera containing high levels of hK2 (>100 ng/ml), hK2 exists as a complex with alpha1-antichymotrypsin with a molecular weight of 90 kDa. The kallikrein also exists as a 32-kDa free form, which includes the precursor pro form of hK2. The relative amount of complex and free hK2 varied, but in most sera examined the 32-kDa form predominated. Recombinant hK2 readily formed complexes with alpha2-macroglobulin when the two proteins were incubated together as well as when hK2 was spiked into female serum.
No takes yet. Share an insight, caveat, or question.
Grauer et al. (1998) conducted an observational in Prostate carcinoma. Detection of hK2 forms was evaluated on Forms of hK2 in serum. In prostate cancer sera with high hK2 levels, hK2 exists as a 90-kDa complex with alpha1-antichymotrypsin and a predominant 32-kDa free form including the precursor prohK2.
Synapse has enriched 10 related papers. Consider them for comparative context: